Endocrine Health Limited 08994426 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is specialists medical practice activities. Digita Accounts Production Advanced 6.30.9574.0 true 08994426 2022-04-01 2023-03-31 08994426 2023-03-31 08994426 core:RetainedEarningsAccumulatedLosses 2023-03-31 08994426 core:ShareCapital 2023-03-31 08994426 core:CurrentFinancialInstruments 2023-03-31 08994426 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 08994426 core:OfficeEquipment 2023-03-31 08994426 core:PlantMachinery 2023-03-31 08994426 core:AllAssociates 2023-03-31 08994426 bus:SmallEntities 2022-04-01 2023-03-31 08994426 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 08994426 bus:FullAccounts 2022-04-01 2023-03-31 08994426 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 08994426 bus:RegisteredOffice 2022-04-01 2023-03-31 08994426 bus:Director1 2022-04-01 2023-03-31 08994426 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 08994426 core:OfficeEquipment 2022-04-01 2023-03-31 08994426 core:PlantMachinery 2022-04-01 2023-03-31 08994426 core:AllAssociates 2022-04-01 2023-03-31 08994426 core:OtherRelatedParties 2022-04-01 2023-03-31 08994426 countries:EnglandWales 2022-04-01 2023-03-31 08994426 core:OfficeEquipment 2022-03-31 08994426 core:PlantMachinery 2022-03-31 08994426 core:AllAssociates 2022-03-31 08994426 2021-04-01 2022-03-31 08994426 2022-03-31 08994426 core:RetainedEarningsAccumulatedLosses 2022-03-31 08994426 core:ShareCapital 2022-03-31 08994426 core:CurrentFinancialInstruments 2022-03-31 08994426 core:CurrentFinancialInstruments core:WithinOneYear 2022-03-31 08994426 core:OfficeEquipment 2022-03-31 08994426 core:PlantMachinery 2022-03-31 08994426 core:AllAssociates 2022-03-31 08994426 core:AllAssociates 2021-04-01 2022-03-31 iso4217:GBP xbrli:pure

Registration number: 08994426

Endocrine Health Limited

Annual Report and Unaudited Filleted Financial Statements

for the Year Ended 31 March 2023

 

Endocrine Health Limited

Contents

Balance Sheet

1 to 2

Notes to the Unaudited Financial Statements

3 to 6

 

Endocrine Health Limited

(Registration number: 08994426)
Balance Sheet
31 March 2023

Note

2023
£

2022
£

Fixed assets

 

Tangible assets

4

2,153

3,325

Current assets

 

Debtors

5

101,640

92,406

Cash at bank and in hand

 

18,365

4,775

 

120,005

97,181

Creditors: Amounts falling due within one year

6

(13,587)

(11,530)

Net current assets

 

106,418

85,651

Net assets

 

108,571

88,976

Capital and reserves

 

Called up share capital

1

1

Retained earnings

108,570

88,975

Shareholders' funds

 

108,571

88,976

 

Endocrine Health Limited

(Registration number: 08994426)
Balance Sheet
31 March 2023

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 28 November 2023
 

.........................................
B Ahmad
Director

 

Endocrine Health Limited

Notes to the Unaudited Financial Statements
Year Ended 31 March 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Spire Hospital Bristol
Redland Hill
Redland
Bristol
BS6 6UT
United Kingdom

These financial statements were authorised for issue by the director on 28 November 2023.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Endocrine Health Limited

Notes to the Unaudited Financial Statements
Year Ended 31 March 2023

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

25% Reducing balance

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2022 - 1).

 

Endocrine Health Limited

Notes to the Unaudited Financial Statements
Year Ended 31 March 2023

4

Tangible assets

Plant and machinery
£

Office equipment
£

Cost or valuation

At 1 April 2022

-

7,448

Additions

259

-

Disposals

-

(2,092)

At 31 March 2023

259

5,356

Depreciation

At 1 April 2022

-

4,123

Charge for the year

-

1,405

Eliminated on disposal

-

(2,066)

At 31 March 2023

-

3,462

Carrying amount

At 31 March 2023

259

1,894

At 31 March 2022

-

3,325

5

Debtors

Note

2023
£

2022
£

Trade debtors

 

5,825

1,591

Amounts owed by related parties

7

95,815

90,815

 

101,640

92,406

 

Endocrine Health Limited

Notes to the Unaudited Financial Statements
Year Ended 31 March 2023

6

Creditors

Creditors: amounts falling due within one year

Note

2023
£

2022
£

Due within one year

 

Taxation and social security

 

5,324

4,100

Other creditors

 

8,263

7,430

 

13,587

11,530

7

Related party transactions

Loans to related parties

2023

Associates
£

At start of period

90,815

Advanced

5,000

At end of period

95,815

2022

Associates
£

Total
£

Advanced

90,815

90,815

At end of period

90,815

90,815

Terms of loans to related parties

Interest free and repayable on demand.